Royal Bank of Canada Issues Pessimistic Forecast for Korro Bio (NASDAQ:KRRO) Stock Price
Korro Bio (NASDAQ:KRRO – Free Report) had its target price cut by Royal Bank of Canada from $105.00 to $95.00 in a research report sent to investors on Wednesday morning,Benzinga reports. They ...
Korro Bio, Inc. (NASDAQ:KRRO) Given Consensus Rating of “Buy” by Analysts
Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned a consensus rating of “Buy” from the seven ...
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
Completed dosing of first two cohorts in Phase 1/2a REWRITE Clinical Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD); Interim ...
Korro Bio, Inc.: KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on ...
Korro Bio gets Orphan Drug Designation from FDA for its genetic disorder treatment
Korro Bio received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat Alpha-1 Antitrypsin ...
Korro Bio's KRRO-110 Gets FDA Orphan Drug Designation
Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is ...
Korro Bio receives ODD from U.S. FDA for AATD
Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...
The Manila Times13d
Global Uranium Corp. Announces Private Placement for up to C$1,000,000
VANCOUVER, British Columbia, March 14, 2025 (GLOBE NEWSWIRE) -- Global Uranium Corp. (CSE: GURN | FRA: Q3J) (the " Company ”) is pleased to announce a non-brokered private placement for gross proceeds ...
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...
Dealbreaker on MSN16d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns about ...
MedCity News17d
Beam Base Editor’s Early Data in Rare Liver Disease Tee Up $500M Stock Sale in Tough Market
Korro Bio recently began a Phase 1/2 test of KRRO-110, an RNA-editing therapy for AATD. Last summer, biotech startup AIRNA raised $60 million to advance to the clinic in 2025 with its experimental ...
The Express Tribune21d
Kings vs Nuggets 110-116: DeRozan makes NBA history despite loss to Denver
Denver Nuggets beat the Sacramento Kings on Wednesday 116-110 in a close encounter on Wednesday night. The Sacramento Kings, without Domantas Sabonis and Malik Monk, fought to an early lead and ...